Drug intelligence / Profile preview

Xinran Meiyu

Development stage: Unknown
Lead developer: Nanfang Hospital, Southern Medical University
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Xinran Meiyu is a topical therapeutic agent evaluated for its efficacy in promoting wound healing and managing post-operative complications following Follicular Unit Extraction (FUE) hair transplantation. In clinical studies, it is compared against standard treatments like mupirocin ointment to assess its impact on healing speed, wound healing rate, and the reduction of symptoms such as pain, itching, erythema, and folliculitis. The product is primarily developed and studied in China, particularly by institutions like Southern Medical University Southern Hospital, for patients with androgenetic alopecia or congenital high hairlines.

Brand names: Xinran Meiyu
Other names: 欣然美域

Beyond the preview

Go deeper on Xinran Meiyu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinran Meiyu.

Explore the full profile